Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by 2019champson Jul 28, 2021 11:26pm
85 Views
Post# 33619304

RE:Current Price $1.38 - Awaiting Human Data

RE:Current Price $1.38 - Awaiting Human DataGood post. We are flying under the radar, which is good and bad. Good in a sense where we can still load up for very cheap. The news releases during the trials were very bullish. I think if it wasn't for a seller or two we would be in the mid $2 range. That also is very cheap considering this is a multi billion dollar market with little to no competition. I think alot of crappy canadian biotech stocks in the "covid space" ruined it for a company like arch (AGN, SONA, to name a few) prime examples of how not to run a company, and investments you don't go near (Alot of pumping, alot of promises, but none delivered). I think some people lost faith in the canadian biotech sector because of a few of these bad apples. Anyways, arch is in a whole league of its own. This is one of those companies when we're trading at $10, ALOT of people will look back and say "Crapp i wish i knew about these guys at $1.30". Data due soon, this is exciting!
<< Previous
Bullboard Posts
Next >>